Search
for
Sort by
Research 91–120 of 1000+
- Peripheral neuropathy associated with tofacitinib use in alopecia universalis
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Therapeutic expansion of JAK inhibitors in Chinese dermatological practice: beyond atopic dermatitis to novel autoimmune frontiers
- Comparative analysis of therapeutic outcomes in pediatric versus adult ophiasis-pattern alopecia areata: A review of treatment modalities and disease course
- An urticarial drug eruption caused by tofacitinib for alopecia universalis
- Chemotherapy-Induced Alopecia Beyond Cytotoxicity: Hair Follicle Immune Privilege Collapse and JAK-STAT Signaling
- Alopecia areata
- Current Treatments for Alopecia Areata
- Assessing Alopecia Areata Management in Poland: Challenges in Medical Practices and Patient Care
- Novel investigational drugs for alopecia areata and future perspectives
- Common Causes of Hair Loss
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not of Plaque Psoriasis with Tofacitinib in a Young Woman
- Alopecia Areata: a Comprehensive Review of Pathogenesis and Management
- Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
- Review of modern methods of treating vitiligo
- Evolving treatment paradigms in dermatology: Insights from emerging and repurposed therapies
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Janus kinase inhibitors for alopecia areata: a review of clinical data
- Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review
- The Role of Janus Kinase Inhibitors in Dermatology
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Various Applications of Tofacitinib and Ruxolitinib (Janus Kinase Inhibitors) in Dermatology and Rheumatology: A Review of Current Evidence and Future Perspective
- Efficacy of Janus kinase inhibitors in adult patients with alopecia areata
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Tofacitinib in the Management of Alopecia Universalis
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- BH20 An unintended sequela of hair regrowth: severe Janus kinase inhibitor-associated acneiform eruption in alopecia areata
- Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata